Key facts
- RedRidge Bio’s last known valuation is $17.6M (Aug 2022).
- It has raised $4.1M; the latest was Early Stage VC in Mar 2025.
- Notable investors include New Enterprise Associates, Laboratoires Pierre Fabre, Sixty Degree Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for RedRidge Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for RedRidge Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RedRidge Bio
Developer of biparatopic antibody therapies designed to enhance efficacy in treating cancer and autoimmune diseases. The company offers precision-engineered antibodies that target two distinct sites on a single protein, enabling healthcare providers to achieve functional inhibition, efficient internalization, and tailored immune modulation for improved patient outcomes.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2021
- Employees
- 15
- Website
- redridgebio.com/
- Ownership
- Privately Held (backing)
RedRidge Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RedRidge Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RedRidge Bio in its N-PORT filings yet. We sweep new filings monthly.